What is the official website of ExecuPharm ?

The official website of ExecuPharm is http://www.execupharm.com.

What is ExecuPharm's cybersecurity risk score?

ExecuPharm has an AI-generated cybersecurity risk score of 717 out of 1000, indicating a Moderate security posture according to Rankiteo's assessment.

How many security incidents has ExecuPharm experienced?

According to Rankiteo, ExecuPharm currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has ExecuPharm been affected by any supply chain cyber incidents ?

According to Rankiteo, ExecuPharm has been affected by a supply chain cyber incident involving Oracle, with the incident ID ORAPAR1766015901.

Does ExecuPharm have SOC 2 Type 1 certification ?

According to Rankiteo, ExecuPharm is not certified under SOC 2 Type 1.

Does ExecuPharm have SOC 2 Type 2 certification ?

According to Rankiteo, ExecuPharm does not hold a SOC 2 Type 2 certification.

Does ExecuPharm comply with GDPR ?

According to Rankiteo, ExecuPharm is not listed as GDPR compliant.

Does ExecuPharm have PCI DSS certification ?

According to Rankiteo, ExecuPharm does not currently maintain PCI DSS compliance.

Does ExecuPharm comply with HIPAA ?

According to Rankiteo, ExecuPharm is not compliant with HIPAA regulations.

Does ExecuPharm have ISO 27001 certification ?

According to Rankiteo,ExecuPharm is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does ExecuPharm operate in ?

ExecuPharm operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does ExecuPharm have ?

ExecuPharm employs approximately 322 people worldwide.

Does ExecuPharm own any subsidiaries ?

ExecuPharm presently has no subsidiaries across any sectors.

How many LinkedIn followers does ExecuPharm have ?

ExecuPharm's official LinkedIn profile has approximately 42,464 followers.

What is the NAICS classification code for ExecuPharm ?

ExecuPharm is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does ExecuPharm have a Crunchbase profile ?

No, ExecuPharm does not have a profile on Crunchbase.

Does ExecuPharm have a LinkedIn profile ?

Yes, ExecuPharm maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/execupharm.

How many cybersecurity incidents has ExecuPharm experienced ?

As of July 18, 2026, Rankiteo reports that ExecuPharm has experienced 2 cybersecurity incidents.

How many peer or competitor companies does ExecuPharm have ?

ExecuPharm has an estimated 5,710 peer or competitor companies worldwide.

What types of cybersecurity incidents has ExecuPharm faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Vulnerability and Ransomware.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

ExecuPharm

Boost Score +25 with badge (5 left)

717

/1000

Moderate

742

/1000

Moderate

ExecuPharm Vendor Cyber Rating & Cyber Score

execupharm.com

Add Your Compliance Badge

ExecuPharm is the North American clinical operations business of Parexel FSP. 10+ years of Experience Meeting Client Needs 10,000+ Global Clinical Operational Specialists In Network 80% of Recruiting Staff with >15 Years of Experience Talent Acquisition, Deployment Rates, and Employee Retention above 90% Management Staff with Tangible Industry Experience Greater Than 95% Repeat Business Average Turnaround Time of 14 Days To Deploy Project Team Resources

ExecuPharm A.I CyberSecurity Scoring

Scoring History

ExecuPharm

ExecuPharm CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

Parexel

Vulnerability

10/2025

Oracle

ORAPAR176601590...

ExecuPharm

Ransomware

3/2020

EXEPAR176974207...

Loading…

A.I.

ExecuPharm Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for ExecuPharm

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for ExecuPharm in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for ExecuPharm in 2026.

Incident Types ExecuPharm vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for ExecuPharm in 2026.

Incident History - ExecuPharm (X = Date, Y = Severity)

Loading…

SUBSIDIARY

ExecuPharm Subsidiaries

ExecuPharm

Pharmaceutical Manufacturing

Website: http://www.execupharm.com

Company Size: 322

ParexelPharmaceutical Manufacturing

Loading…

ExecuPharm Similar Companies

Teva Pharmaceuticals

tevapharm.com

Teva Pharmaceuticals is a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how we make it happen, visit www.tevapharm.com. Our community guidelines may be found here: https://www.tevapharm.com/news-and-media/teva-social-media-guidelines/ Please note that adverse effects for any of our products should be reported at: https://www.tevapharm.com/teva-medical-information/report-a-side-effect-form/ Product-specific questions should be directed to Teva or Teva Group subsidiaries in your country. Contact details and Teva's Pharmacovigilance Privacy Policy may be found here: http://www.tevapharm.com/contact_us/

Bristol Myers Squibb

cb bms.com

At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients. Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do. Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html

AUROBINDO PHARMA LTD

aurobindo.com

Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and markets a wide range of generic pharmaceuticals, branded specialty drugs, and active pharmaceutical ingredients (APIs) across more than 150 countries. It is ranked among the top 10 generic companies in eight European nations and holds the distinction of being the largest generic pharmaceutical company in the United States. With over 30 state-of-the-art manufacturing and packaging facilities approved by leading global regulatory authorities including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, and Brazil ANVISA, Aurobindo Pharma ensures the highest standards of quality. Its robust portfolio spans eight major therapeutic areas: Central Nervous System (CNS), Antiretroviral (ARV), Cardiovascular (CVS), Antibiotics, Gastroenterology, Anti-diabetics, Oncology, and Dermatology, supported by a strong R&D infrastructure that drives innovation, affordability, and accessibility.

Dr. Reddy's Laboratories

drreddys.com

Established in 1984, we are a global pharmaceutical company headquartered in Hyderabad, India. Driven by our purpose of ‘Good Health Can’t Wait’, we work to provide access to affordable and innovative medicines. We offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major markets include USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in future growth drivers such as access to novel molecules, digital therapeutics and consumer healthcare. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com. Caution Notice: Dr. Reddy's has been made aware of candidates receiving fraudulent job opportunities from unauthorised recruiting agencies or people impersonating Dr. Reddy's leaders. These fraudulent jobs may be advertised on employment sites or mimic our careers site and company email addresses. Please know that Dr. Reddy's Laboratories has no affiliation or connection to these situations. Dr. Reddy's (and its associated/group companies) follows a formal recruitment process through its own HR department. Please report immediately in case you suspect a fraudulent job. You may raise your concern by: Accessing https://drreddys.ethicspoint.com. Calling on the hotline number. List of hotline numbers are available in https://drreddys.ethicspoint.com. The hotline is available 24x7 in multiple languages. Writing to [email protected] or [email protected]. For our community guidelines on LinkedIn, please visit: https://shorturl.at/LTvNZ

Merck

merck.us

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com. This site is intended for residents of the United States and Canada and their territories only. FLS: http://merck.us/3TKXNuZ

Hikma Pharmaceuticals

cb hikma.com

For almost 50 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 800* high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing plants, 3 R&D hubs and c9,500 employees worldwide. *As of December 2025 Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668 For all product information and enquiries, please contact us at [email protected]

Servier

servier.com

Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its vocation of being committed to therapeutic progress to serve patient needs while adopting a long-term vision. Its employees are fully committed to this shared vocation, which serves as a source of inspiration every day. A world leader in cardiometabolism and venous diseases, Servier has made a major shift into oncology, which represents a new pillar of strategic growth. The Group devotes close to 70% of its R&D budget to this field, with the ambition of becoming a focused and innovative player in the development of treatments targeting rare cancers. Neurology will constitute a future growth driver. Servier is focusing on a limited number of diseases in this area where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote widespread access to quality care at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, and Eastern Europe. In all these areas, the Group takes patient considerations into account at every stage of the medicine life cycle. Headquartered in France, Servier relies on committed teams and strong geographical footprint; its medicines are available in close to 140 countries. In 2023/2024, the Group achieved sales revenue of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%). Today, the Group employs over 22,000 people worldwide. -- To report a suspected adverse event with a Servier drug, please visit servier.com

Ipca Laboratories Limited

ipca.com

A consumer-led global pharmaceutical company, creating healthy doses of life since 1949. When you operate in an industry like pharmaceuticals, your work goes way beyond creating ‘products for customers’. It is different from any other domain – there lies a higher sense of responsibiliti and a need for utmost integriti in everything you do. As you serve millions of lives, high qualiti standards become a pre-requisite, and safeti of your people and consumers always comes first. All this, while ensuring that each life you touch is treated with respect and digniti. For more than 60 years, Ipca has been a crucial healthcare partner in over 120 countries across the 6 continents. We are a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments. Today, we are one of the world’s largest manufacturers and suppliers of over a dozen APIs. These are produced from scratch at fully-automated manufacturing facilities, approved by the world’s most discerning drug regulatory authorities like UK-MHRA, EDQM-Europe, and WHO-Geneva, among others. - One of the largest suppliers of these APIs worldwide with manufacturing leadership in over 12 APIs globally - 15 APIs & 11 Formulations manufacturing facility across the globe Leader in DMARDs (Disease Modifying Anti-Rheumatic Drugs) treatment for Rheumatoid Arthritis - Leading brands in Pain, Rheumatology, Antimalarials and Hair care therapy - 4 formulations rank amongst the top 300 brands of IPM as per IQVIA

Zoetis

zoetis.com

The world’s leading animal health company. We’ve been innovating ways to predict, prevent, detect, and treat animal illness for over 70 years, and we continue to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers. Our leading portfolio and pipeline makes a difference in over 100 countries. Community Guidelines: This page is intended to share how Zoetis is advancing care for animals. We aspire to create a supportive community, but there are guidelines to which posts and comments on this page must adhere. If your post references a side effect related to any Zoetis product, we may contact you for more information. To monitor the safety of Zoetis products, we advise you to call our Veterinary Medical Information and Product Support Team at 1-888-963-8471; Support Team is available Mon-Fri 9am to 6:30pm ET. We reserve the right to remove any post/comment that violates LinkedIn Guidelines. As a last resort, we reserve the right to block users that demonstrate a repeated pattern of violating LinkedIn’s spirit of constructive, professional discourse. We respectfully request that you refrain from posting comments including: Unsolicited and/or unverified medical advice Vulgarity and/or profanity Discriminatory and/or derogatory comments, hate speech Politics and religion Personal attacks and/or threats Promotion of illegal activity Copyright/trademark infringements Topics that may be considered spam/advertising Our regular business hours are Mon-Fri 9am to 5pm ET. Zoetis does not endorse and is not responsible for information and opinions shared by community members. The information shared is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. Testimonials represent individual experience only and the experiences and opinions of community members may be unique to the speaker. Terms of Use: https://www.zoetis.com/terms-of-use

Loading…

NEWS

ExecuPharm CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

November 08, 2024 03:28 AM

Cybercriminals Leak ExecuPharm Internal Documents After Ransomware Attack

A successful ransomware attack was deployed on March 13 against ExecuPharm, a subsidiary of the US Biopharmaceutical giant Parexel.

Read Article

August 16, 2024 07:00 AM

Understanding healthcare data breach lawsuit trends

Lawsuits often follow a healthcare data breach, but understanding what drives litigation trends can help healthcare organizations prepare.

Read Article

September 20, 2022 07:00 AM

Data breach, but no identity theft: Can employee still sue?

An important new ruling says an employee can sue her employer even though a data breach did not lead to identity theft or fraud.

Read Article

April 29, 2020 07:00 AM

ExecuPharm, Subsidiary of US Biopharmaceutical Giant Parexel, Hit by Ransomware Attack

ExecuPharm, a subsidiary of the U.S. Biopharmaceutical giant Parexel, has been hit by a ransomware attack according to a recent announcement...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-57980

SUMMARY

Authentication bypass using an alternate path or channel in Microsoft Edge (Chromium-based) allows an unauthorized attacker to perform tampering over a network.

Published

Date2026-07-17

Updated

Date2026-07-17

RISK INFORMATION (Score: 5.4)

cvss3

Base Score: 5.4

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:L/I:L/A:N

Impact Score

2.5

Exploitability

2.8

REFERENCES

https://msrc.microsoft.com/update-guide/vulnerability/CVE-2026-57980

CVE-2026-56741

SUMMARY

JLine is a Java library for handling console input. Prior to 3.30.14, 4.0.16, and 4.2.1, the JLine3 Telnet server remote-telnet module does not apply an upper bound to terminal dimensions received via the Telnet NAWS option, and TelnetIO.handleNAWS() in TelnetIO.java:856-879 reads client-supplied width and height as 16-bit unsigned integers and passes values such as 65535x65535 to setTerminalGeometry(), allowing an unauthenticated remote attacker to repeatedly alternate values and trigger continuous expensive rendering work that causes CPU exhaustion and denial of service. This issue is fixed in versions 3.30.14, 4.0.16, and 4.2.1.

Published

Date2026-07-17

Updated

Date2026-07-17

RISK INFORMATION (Score: 7.5)

cvss3

Base Score: 7.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

3.9

REFERENCES

CVE-2026-56740

SUMMARY

JLine is a Java library for handling console input. Prior to 3.30.14, 4.0.16, and 4.2.1, the JLine3 Telnet server remote-telnet module does not limit the number of environment variables a client may inject via the Telnet NEW-ENVIRON option, and TelnetIO.readNEVariables() in TelnetIO.java:1127-1180 stores each variable pair in a HashMap held by ConnectionData, allowing an unauthenticated attacker to flood unique variable pairs before the terminating IAC SE byte and exhaust JVM heap memory with an OutOfMemoryError. This issue is fixed in versions 3.30.14, 4.0.16, and 4.2.1.

Published

Date2026-07-17

Updated

Date2026-07-17

RISK INFORMATION (Score: 7.5)

cvss3

Base Score: 7.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

3.9

REFERENCES

CVE-2026-56171

SUMMARY

Exposure of private personal information to an unauthorized actor in Windows RDP allows an unauthorized attacker to disclose information over a network.

Published

Date2026-07-17

Updated

Date2026-07-17

RISK INFORMATION (Score: 7.1)

cvss3

Base Score: 7.1

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:H/I:L/A:N

Impact Score

4.2

Exploitability

2.8

REFERENCES

https://msrc.microsoft.com/update-guide/vulnerability/CVE-2026-56171

CVE-2026-54335

SUMMARY

Feathersjs is a framework for creating web APIs and real-time applications with TypeScript or JavaScript. In 5.0.44 and earlier, the _.merge(target, source) utility exported by @feathersjs/commons recursively merges source into target by iterating Object.keys(source). When source was produced by JSON.parse and contains a __proto__, constructor, or prototype key, that key is returned as an own-enumerable property; the recursive merge then resolves target['__proto__'] to Object.prototype and writes attacker-supplied properties onto it, polluting the prototype for all plain objects in the process for the lifetime of the Node process. This issue is fixed in version 5.0.45.

Published

Date2026-07-17

Updated

Date2026-07-17

RISK INFORMATION (Score: 3.7)

cvss3

Base Score: 3.7

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:N/I:L/A:N

Impact Score

1.4

Exploitability

2.2

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…